Evelo Biosciences, Inc.(EVLO)
$0.00—Stale · unknown oldEarnings today
Evelo Biosciences, Inc.(EVLO)
NASDAQ • Last print unknown ago
$0.00—Stale · unknown oldEarnings today
Buy8 analysts
Key Metrics
TTMMarket Cap$1.9K
Revenue TTM$0.00
Price / Sales—
Net Income TTM-$82.35M
Free Cash Flow-$73.99M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-6232.8%
Return on Assets-177.7%
Debt / Equity (MRQ)-10.24
Current Ratio (MRQ)4.16
EPS TTM$-26.28
PRICE
Prev Close
0.00
Open
0.00
Day Range0.00 – 0.00
0.00
0.00
52W Range0.00 – 0.00
0.00
0.00
0% of range
50-Day MA
0.00(+6.3%)
200-Day MA
0.00(-50.3%)
VOLUME & SIZE
Avg Volume
194
FUNDAMENTALS
P/E (TTM)
-0.0x
Not profitable
EPS (TTM)
—
Div Yield (TTM)
No dividend
Beta
1.20
Market-like
TECHNICAL
RSI (14)
51
Bullish momentum
Upcoming Events
EEarnings Report
Today
Aug 31
DEx-Dividend
In 88 days
Nov 27
PDividend Pay
In 88 days
Nov 27
EVLO News
About
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Industry
Research and Development in Biotechnology
Website
Douglas MaslinSenior Director & Immunology Clinical Lead
Leslie Wardwell-ScottVice President and Head of Corporate Development & Strategic Integration
Andrea ItanoHead of Research
Chun ZhangChief Technical Operations & Quality Officer
Duncan McHale MBBSChief Medical Officer
Craig R. Jalbert CIRAPresident, Secretary, Principal Executive, Financial and Accounting Officer & Director